Spirometer Market

The Spirometer Market was valued at USD 1.07 billion in 2025 and is projected to reach USD 1.80 billion by 2032. The market is expected to grow at a CAGR of 7.7% during the forecast period.

Market Introduction and Overview

The spirometer market comprised diagnostic devices and associated software, sensors, and consumables used to measure lung volume, airflow, and related pulmonary function parameters in clinical and home-based settings. Market growth was driven by the rising burden of chronic respiratory disorders, especially COPD and asthma, the expansion of preventive respiratory screening, and broader use of pulmonary function testing in outpatient and occupational health programs. Spirometry remained a core diagnostic method in respiratory assessment, supported by established international testing standards and its importance in confirming airflow limitation and monitoring disease progression. Product development increasingly moved toward handheld, wireless, and software-connected systems that improved portability, data transfer, test coaching, and remote patient monitoring. Demand also strengthened as providers adopted digital respiratory pathways and decentralized care models. The medium-term outlook remained favorable, supported by aging populations, higher awareness of lung health, and continuing integration of spirometry into primary care, specialty care, and home monitoring workflows.

Spirometer Market Segmentation, by Type

Based on type, the market has been divided into Handheld Spirometers, Table Top Spirometers, Desktop Spirometers, and Wireless Spirometers. Among these, the Handheld Spirometers sub-segment was projected to generate the maximum revenue. The handheld spirometer sub-segment witnessed the highest market share in the global spirometer market in 2025. Its dominance had been supported by portability, lower acquisition cost, faster point-of-care deployment, and easier use across primary care, pulmonology clinics, home healthcare, and occupational screening programs. Handheld systems had also benefited from growing demand for early COPD and asthma detection outside centralized pulmonary laboratories. Their compact format supported community screening, telehealth-linked diagnostics, home monitoring, and follow-up testing in chronic respiratory care pathways. Technology improvements in battery life, Bluetooth connectivity, app-based coaching, and automated report generation had further improved adoption across both developed and emerging healthcare markets. As providers aimed to expand respiratory testing volumes while reducing workflow complexity, handheld spirometers had remained the most commercially attractive format in 2025.

Spirometer Market Segmentation, by Application

Based on application, the market has been divided into Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Pulmonary Fibrosis, Lung Function Testing, Occupational Health, and Other Respiratory Applications. Among these, the Chronic Obstructive Pulmonary Disease sub-segment was projected to generate the maximum revenue. The COPD sub-segment witnessed the highest market share in the global spirometer market in 2025. This segment had dominated because spirometry remained central to the clinical assessment of airflow obstruction and long-term respiratory monitoring in COPD care pathways. Rising disease burden, aging populations, smoking-related lung impairment, and stronger emphasis on earlier diagnosis had increased testing demand across hospitals, pulmonary clinics, and community settings. COPD management also required repeated lung-function measurement, which supported recurring device utilization and consumables demand. As healthcare systems prioritized earlier identification of chronic respiratory decline and reduction of exacerbation-related hospitalization, COPD-focused spirometry had remained the largest application area in 2025.

Spirometer Market Regional Analysis

North America region dominated the market in the year 2025, and it was expected to continue its dominance during the forecast period. The spirometer market in North America had witnessed strong demand because the region combined a high diagnosed burden of COPD and asthma with advanced respiratory care infrastructure and wider access to pulmonary diagnostics. The region had also benefited from higher healthcare expenditure, earlier adoption of digital and home-based spirometry, and faster commercialization of connected respiratory monitoring platforms. Hospitals, outpatient centers, clinical laboratories, and homecare providers had incorporated spirometry into both diagnostic and follow-up workflows, particularly for COPD case finding, asthma management, and remote pulmonary monitoring. North America also held an advantage through the concentration of major respiratory diagnostics suppliers, stronger regulatory pathways for device launches, and more mature reimbursement and screening ecosystems. These factors had supported larger installed device bases, higher recurring consumables use, and broader adoption of both clinic-based and portable spirometry systems in 2025.

Spirometer Market Scope: Inquire before buying

Key Players/Competitors Profiles Covered in the Spirometer Market Report in Strategic Perspective

1. MGC Diagnostics Corporation

2. Vitalograph Ltd.

3. ndd Medizintechnik AG

4. Schiller AG

5. COSMED Srl

6. MIR Medical International Research

7. NuvoAir AB

8. Monitored Therapeutics, Inc.

9. Clario

10. Medikro Oy

11. Fukuda Sangyo Co., Ltd.

12. CHEST M.I., Inc.

13. Futuremed America, Inc.

14. SDI Diagnostics, Inc.

15. Jones Medical Instrument Company

16. KoKo PFT

17. Micro Direct Ltd.

18. SIBELMED

19. Vyaire Medical, Inc.

20. Midmark Corporation

21. Contec Medical Systems Co., Ltd.

22. Bionet Co., Ltd.

23. Microlife Corporation

24. Spirohome AG

25. CMI Health Inc.

Recent Developments

January 2025 MIR entered a new ownership phase through investment and acquisition by Quadrivio Group’s Silver Economy Fund. The transaction strengthened MIR’s financial capacity for international growth in respiratory diagnostics and supported further expansion in spirometry, telehealth-oriented pulmonary monitoring, and product development focused on aging populations and chronic respiratory care.

December 2024 ndd Medical launched EasyOne Sky, a new spirometry solution designed with built-in coaching, TrueFlow measurement technology, and cloud connectivity. The launch reflected the market’s move toward easier-to-use, digitally connected respiratory diagnostics that support earlier COPD detection, workflow efficiency, and wider deployment across outpatient and decentralized care settings.

September 2024 Vitalograph acquired Morgan Scientific to strengthen its U.S. commercial footprint and expand advanced pulmonary diagnostic capabilities. The deal improved its reach in pulmonary function testing and reinforced the trend toward platform expansion, geographic strengthening, and tighter integration of spirometry with broader respiratory diagnostic portfolios in North America.

June 2024 Clario received U.S. FDA 510(k) clearance for SpiroSphere with wireless ECG integration. This development improved simultaneous respiratory and cardiac data capture in clinical trials and highlighted growing demand for portable, connected spirometry systems that reduce site burden, improve patient usability, and streamline high-quality digital data collection.

January 2024 NuvoAir announced FDA clearance for in-home use of its Air Next Spirometer. The milestone supported broader deployment of home-based lung function monitoring and expanded the clinical usability of full spirometry outside conventional care settings, reinforcing the market shift toward remote respiratory management and decentralized chronic disease monitoring.

February 2024 Monitored Therapeutics announced NMPA approval for the GoSpiro spirometer in China, expanding access to validated home spirometry in a major respiratory care market. The development also signaled rising international demand for remote-monitoring spirometers that support clinical trials, chronic disease tracking, and more scalable patient monitoring beyond hospital walls.